Transporter gene knockout rats are practically advantageous over murine models for pharmacokinetic and excretion studies, but their phenotypic characterization is lacking. At present, relevant aspects of pharmacokinetics, metabolism, distribution, and excretion of transporter probes [P-glycoprotein (P-gp): loperamide and paclitaxel; breast cancer resistance protein (Bcrp): sulfasalazine; and multidrug resistance-associated protein 2 (Mrp2): carboxydichlorofluorescein] were studied systematically across SAGE P-gp, Bcrp, and Mrp2 knockout rats. In Mdr1a knockout rats, loperamide and paclitaxel oral bioavailability was 2-and 4-fold increased, respectively, whereas clearance was significantly reduced (40-42%), consistent with the expected 10-to 20-fold reduction in paclitaxel excretion. N-Desmethyl-loperamide pharmacokinetics were not altered in any of the three knockouts after oral loperamide. In rats lacking P-gp, paclitaxel brain partitioning was significantly increased (4-fold). This finding is consistent with observations of loperamide central nervous system opioid pharmacology in Mdr1a knockout rats. Sulfasalazine oral bioavailability was markedly increased 21-fold in Bcrp knockouts and, as expected, was also 2-to 3-fold higher in P-gp and Mrp2 knockout rats. The sulfapyridine metabolite/parent ratio was decreased 10-fold in rats lacking Bcrp after oral, but not intravenous, sulfasalazine administration. Carboxydichlorofluorescein biliary excretion was obliterated in Mrp2 knockout rats, resulting in 25% decreased systemic clearance and 35% increased half-life. In contrast, carboxydichlorofluorescein renal clearance was not impaired in the absence of Mrp2, Bcrp, or P-gp. In conclusion, SAGE Mdr1a, Bcrp, and Mrp2 knockout rats generally demonstrated the expected phenotypes with respect to alterations in pharmacokinetics of relevant probe substrates; therefore, these knockout rats can be used as an alternative to murine models whenever a larger species is practically advantageous or more relevant to the drug discovery/development program.
Introduction
Transporter knockout mice have been used extensively to study the role of transporters in drug pharmacokinetics, distribution, and excretion (Klaassen and Lu, 2008) . Murine models are well suited for the study of drug distribution into key organs; for example, the importance of P-gp in limiting blood-brain barrier penetration of substrate drugs was first recognized after Mdr1a knockout mice exhibited 87-fold greater CNS exposure to the P-gp substrate ivermectin, resulting in 100-fold enhanced neurotoxicity (Schinkel et al., 1994) . Although mice are practical for routine measurement of drug distribution typically at a single time point at steady state, they are not optimal for sample-intensive determination of a pharmacokinetic time course or for the study of drug excretion because of their small size and limited volume of relevant bodily fluids (Davies and Morris, 1993) . Thus, a larger species, such as rat, is preferred for the conduct of pharmacokinetic and excretion studies in the drug discovery and development setting.
Rats are the most common rodent toxicology and pharmacokinetic species and are also commonly used in preclinical pharmacology studies. Rats are far easier than mice to manipulate surgically, their total blood volume is sufficient for thorough characterization of pharmacokinetics within a single animal, and they also yield adequate amounts of urine and bile for routine drug excretion studies using metabolism cages (Davies and Morris, 1993) . The recent development of zinc finger nuclease technology enabled rapid generation of targeted gene knockout rats (Geurts et al., 2009 ). Mdr1a zinc finger nucleases were used to develop a proprietary P-gp knockout Wistar rat, which exhibited the expected alterations in the pharmacokinetics and CNS distribution of substrate drugs (Chu et al., 2012) . Mdr1a, Bcrp, and Mrp2 knockout rats recently became commercially available in the Sprague-Dawley strain, which is also commonly used in toxicology, pharmacokinetic, and excretion studies (Mdr1a, Bcrp, and Mrp2 Knockout Rat Data Sheets, 2011; http://www.sageresearchmodels. com) .
Because of the relevance of rats to drug discovery and development, as well as experimental convenience over mice, commercially available Mdr1a, Bcrp, and Mrp2 knockout rats are potentially important preclinical models. However, to date, their phenotypic characterization is largely lacking. In a recent study, SAGE Mdr1a knock-out rats demonstrated good agreement with an established murine model in the extent of P-gp-limited CNS exposure of seven probe substrates (Bundgaard et al., 2012) ; however, phenotypic validation of these Mdr1a knockout rats in terms of P-gp-limited intestinal absorption, distribution in other tissues, and excretion remains to be demonstrated. Finally, functional characterization of SAGE Bcrp and Mrp2 knockout rats is completely absent in the literature.
At present, relevant aspects of loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics, metabolism, distribution, and excretion were systematically studied across SAGE Mdr1a, Bcrp, and Mrp2 knockout rats. These studies not only examined the relevant knockout phenotype but also investigated potentially unexpected compensatory changes. Loperamide and paclitaxel were used as P-gp probe substrates. In Mdr1a knockout models, loperamide intestinal permeability was increased 3.1-fold, CNS partitioning was markedly increased 22-to 107-fold, and intravenous exposure was 1.3-to 2-fold higher (Adachi et al., 2003; Chu et al., 2012) . Likewise, absorption, distribution, and excretion of paclitaxel are affected by P-gp; in Mdr1a knockout mice oral bioavailability was increased 3.1-fold, clearance was decreased 50%, consistent with decreased excretion, and CNS distribution was on average increased 2-fold (Sparreboom et al., 1997; Gallo et al., 2003) . Sulfasalazine was used to investigate Bcrp function, because it has low oral bioavailability limited by intestinal apical efflux primarily via Bcrp (Zaher et al., 2006) . In Bcrp knockout mice, sulfasalazine bioavailability was increased 9-fold (4% versus 37%); intestinal absorption was also modestly increased 1.6-fold in P-gp knockout mice and 3-fold by inhibition of Mrp2 (Zaher et al., 2006; Dahan and Amidon, 2009 ). Carboxydichlorofluorescein was used as a probe for in vivo Mrp2 function, because it is metabolically stable and Mrp2-mediated biliary excretion is a substantial contributor to overall systemic clearance (Zamek-Gliszczynski et al., 2003; Nezasa et al., 2006) .
In the present studies, SAGE Mdr1a, Bcrp, and Mrp2 knockout rats generally demonstrated the expected phenotypes with respect to alterations in pharmacokinetics of relevant probe substrates. The data overall support the use of these knockout rats as an alternative to murine models whenever a larger species is practically advantageous or more relevant.
Materials and Methods
Chemicals. Paclitaxel from Taxus yannanensis, loperamide, and 5-(and 6)-carboxy-2Ј,7Ј-dichlorofluorescein (mixed isomers) were purchased from Sigma-Aldrich (St. Louis, MO). Sulfasalazine and sulfapyridine were purchased from MP Biomedicals (Solon, OH). N-Desmethyl-loperamide was purchased from Toronto Research Chemicals (North York, ON, Canada). All other chemicals were of reagent grade and were readily available from commercial sources.
Animals. Male Sprague-Dawley and Wistar wild-type rats (250 -350 g) were purchased from Harlan (Indianapolis, IN). Male Sprague-Dawley Mdr1a, Bcrp, and Mrp2 knockout rats were purchased from SAGE (St. Louis, MO). Male Mrp2-deficient Wistar rats (TR Ϫ rats) were purchased from RRRC (Columbia, MO). Femoral artery and femoral vein cannulations were performed for blood sampling and intravenous dosing, respectively. In biliary excretion studies, bile ducts were also cannulated. Surgeries on wild-type rats were performed by Harlan, and gene knockout and TR Ϫ rat surgeries were performed by Covance, Inc. (Greenfield, IN) . In all experiments, knockout rats and relevant wild-type controls were matched for age and body weight. Rats were allowed to recover for a minimum of 2 days after surgeries (for wild-type rats, a minimum of 4 days was allowed because of additional postshipment acclimation). The Institutional Animal Care and Use Committees at Covance and Harlan approved all animal procedures.
Loperamide Pharmacokinetics. The plasma concentration time course was determined over 24 h in an intravenous/oral crossover study with a 3-day washout period between drug administration. On day 0, loperamide was administered by intravenous bolus injection (1 mg/kg; 2 ml/kg saline with 0.2 M equivalents of HCl) and on day 3 by oral gavage (10 mg/kg; 10 ml/kg water with 0.2 M equivalents of HCl). Arterial blood samples were collected at the following times after dose administration: 0 (oral arm only), 0.08 (intravenous arm only), 0.25, 0.5, 1, 2, 4, 8, 12 , and 24 h, and the resulting plasma was analyzed for both loperamide and N-desmethyl-loperamide metabolite.
Paclitaxel Pharmacokinetics. The plasma concentration time course was determined over 24 h in an intravenous/oral crossover study with a 3-day washout period between drug administration. On day 0, paclitaxel was administered by intravenous bolus injection (1 mg/kg; 2 ml/kg 50% Cremophor EL in ethanol) and on day 3 by oral gavage (5 mg/kg; 10 ml/kg 50% Cremophor EL in ethanol). Arterial blood samples were collected at the following times after dose administration: 0 (oral arm only), 0.08 (intravenous arm only), 0.25, 0.5, 1, 2, 4, 8, 12 , and 24 h. In a separate study after oral dosing of paclitaxel (5 mg/kg; 10 ml/kg 50% Cremophor EL in ethanol), rats were sacrificed at 1 and 4 h to collect brain, liver, kidneys, and blood. In a separate study, after intravenous bolus injection of paclitaxel (1 mg/kg; 2 ml/kg 50% Cremophor EL in ethanol) to bile duct-cannulated rats housed in metabolism cages, urine, bile, and feces were collected in toto for 0 to 24 h, cages were washed and fluid was collected for analysis at 24 h, and arterial plasma was sampled at the following times after dose administration: 0. 08, 0.25, 0.5, 1, 2, 4, 8, 12 , and 24 h.
Sulfasalazine Pharmacokinetics. The plasma concentration time course was determined over 24 h in an intravenous/oral crossover study with a 3-day washout period between drug administration. On day 0, sulfasalazine was administered by intravenous bolus injection (5 mg/kg; 2 ml/kg water with pH adjusted to 9 -10 with 5 N NaOH) and on day 3 by oral gavage (20 mg/kg; 10 ml/kg 0.5% carboxymethyl cellulose in phosphate-buffered saline, pH 7.4). Arterial blood samples were collected at the following times after dose administration: 0 (oral arm only), 0.08 (intravenous arm only), 0.25, 0.5, 1, 2, 4, 8, 12, and 24 h, and the resulting plasma was analyzed for both sulfasalazine and sulfapyridine metabolite.
Carboxydichlorofluorescein Pharmacokinetics. The plasma concentration time course was determined after intravenous bolus injection of carboxydichlorofluorescein (3 mg/kg; 2 ml/kg 50 mM phosphate buffer, pH 8). Arterial blood samples were collected at the following times after dose administration: 2. 5, 5, 7.5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180 , and 240 min. Rats were housed in metabolic cages over the duration of the 4-h study to enable in toto 0 to 4 h collection of urine and feces. In a separate study after bolus injection of carboxydichlorofluorescein (3 mg/kg; 2 ml/kg 50 mM phosphate buffer, pH 8) to bile duct-cannulated rats housed in metabolism cages, urine, bile, and feces were collected in toto for 0 to 4 h, cages were washed and fluid was collected for analysis at 4 h, and arterial plasma was sampled at the following times after dose administration: 2. 5, 5, 7.5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, and 240 min. Carboxydichlorofluorescein In Vitro Studies. Carboxydichlorofluorescein (1 M) unbound fraction in rat plasma was determined by equilibrium dialysis as described previously (Zamek-Gliszczynski et al., 2012) . Metabolic stability was assessed in mouse and rat liver microsomes and hepatocytes. In brief, carboxydichlorofluorescein was incubated in microsome suspension (0.5 mg/ml microsomal protein; 2 M carboxydichlorofluorescein concentration; 0.5 h) or cryopreserved hepatocyte suspension (0.5 million cells/ml; 2 M carboxydichlorofluorescein; 4-h time course) at 37°C. Incubations were stopped by addition of an equal volume of acetonitrile; parent concentrations were determined by LC-MS/MS, and, in addition, samples were profiled for parent-related metabolite(s) using LC-MS/MS.
Bioanalysis. Loperamide, N-desmethyl-loperamide, paclitaxel, sulfasalazine, sulfapyridine, and carboxydichlorofluorescein concentrations in relevant matrices (plasma, bile, urine, feces, cage wash, and tissue homogenates of brain, kidney, or liver) were quantified by LC-MS/MS. All samples were mixed with an organic internal standard solution to precipitate protein and centrifuged, and the resulting supernatants were directly analyzed. Analytes were separated using reverse-phase chromatography with gradient elution from the following columns: for paclitaxel, Betasil C18 (2.1 ϫ 20 mm, 5 m; Thermo Fisher Scientific, Waltham, MA); for loperamide, N-desmethyl-loperamide, and carboxydichlorofluorescein, Betasil Javelin C18 (2 ϫ 20 mm, 5 m; Thermo Fisher Scientific); and for sulfasalazine and sulfapyridine, Atlantis T3 (2.1 ϫ 50 mm, 5 m; Waters, Milford, MA). All analytes were detected in positive ion mode, except that carboxydichlorofluorescein was detected in negative ion mode, using selected reaction monitoring (Sciex API 4000 triple quadrupole mass spectrometer equipped with a TurboIonSpray interface; Applied Biosystems/MDS, Foster City, CA): paclitaxel 854.3 3 286.3 m/z, loperamide 477.1 3 266.1 m/z, N-desmethyl-loperamide 463.2 3 252.2 m/z, sulfasalazine 399.1 3 119.0 m/z, sulfapyridine 250.1 3 65.1 m/z, and carboxydichlorofluorescein 442.9 3 362.9 m/z. The dynamic range of the assays was 1 to 5000 ng/ml in all matrices for all analytes, except for carboxydichlorofluorescein (25-50,000 ng/ml). Samples with analyte concentrations above the upper limit of quantification were diluted with matrix to within the assay range; concentrations below the lower limit of quantification were reported as such. All bioanalytical assays met prespecified criteria for accuracy (ϽϮ30% relative error) and precision (Ͻ30% relative S.D.).
Data Analysis. Noncompartmental pharmacokinetic parameters were calculated using Watson (version 7.4; Thermo Fisher Scientific). Renal clearance values were calculated as the ratio of total amount excreted in urine and systemic exposure. Excel 2007 (Microsoft, Redmond, WA) was used for all statistical analyses. The Student's two-tailed t test with the Bonferroni correction for multiple comparisons was used to assess statistical significance between knockouts and relevant wild-type controls. In cases in which variance was different between compared groups (F-test, p Ͻ 0.05), the unequal variance t test with the Bonferroni correction for multiple comparisons was used. The minimal criterion for significance was p Ͻ 0.05. All data are reported as means Ϯ S.D.
Results
Pharmacokinetics of loperamide and its N-desmethyl metabolite are summarized in Fig. 1 and Table 1 . In Mdr1a knockout rats, loperamide clearance was on average 40% reduced, and oral absorption was more extensive and protracted (2.2-2.7-fold increase in bioavailability, C max , and T max ). N-Desmethyl-loperamide pharmacokinetics were not significantly altered in any of the three knockouts after oral loperamide. Mdr1a knockout rats exhibited hallmark opioid central effects. After intravenous administration of loperamide, independent veterinary staff noted that all animals corresponding to the Mdr1a knockout group became lethargic but were alert and responsive and recovered by the 6-h time point. Loperamide central effects were more pronounced after oral administration. One to 2 h after dosing, Mdr1a knockout rats were hypoactive, exhibited eye protrusion and lacrimation, as well as shallow breathing, and would respond only when handled. One of the Mdr1a knockout animals was found dead at the 4-h time point, whereas all the others were in a stupor, and so all these animals were discontinued from the study. No central opioid effects were noted in wild-type, Bcrp and Mrp2 knockout rats after either intravenous or oral dosing. These findings are difficult to explain solely by the 2-to 4-fold increased loperamide exposures in Mdr1a knockout rats, because no central effects were observed in P-gpcompetent rats receiving oral loperamide despite 6-to 8-fold higher exposures compared to intravenous administration. Oral exposure in P-gp-competent rats was up to 4.2-fold higher than intravenous exposure in Mdr1a knockouts, in which central opioid effects were noted. The observed opioid pharmacology in Mdr1a knockout rats is therefore consistent with enhanced CNS distribution of loperamide.
Paclitaxel pharmacokinetic and excretory parameters are summarized in Table 2 , and brain/plasma concentration ratios are presented in Fig. 2 . Paclitaxel clearance was 40% lower in Mdr1a knockout rats. On average, 6.2 Ϯ 2.1 and 0.35 Ϯ 0.21% of the paclitaxel intravenous dose was recovered over 24 h in excreta of bile duct-cannulated wild-type and Mdr1a knockout rats, respectively. Decreased excretion of paclitaxel is conceptually consistent with the decreased systemic clearance in Mdr1a knockout rats; however, the 24-h excreta collection period was too short relative to the 7.2-to 12-h half-life to be representative of mass balance (Sparreboom et al., 1997) . Oral absorption was more extensive in Mdr1a knockout rats with a 4-to 5-fold increase in bioavailability and C max . Paclitaxel brain partitioning was increased 4-fold in rats lacking P-gp, consistent with observations of loperamide central effects. Despite decreased biliary and urinary recovery of paclitaxel, liver and kidney partitioning was not altered significantly in Mdr1a knockout rats (Fig. 3) . Brain, liver, and kidney partitioning of paclitaxel was not altered in Bcrp knockout rats, but, surprisingly, liver partitioning was 61% decreased in rats lacking Mrp2.
Sulfasalazine and sulfapyridine metabolite pharmacokinetics are summarized in Fig. 4 and Table 3 . Oral bioavailability was 21-fold higher in Bcrp knockout rats and was also modestly increased 2-to 3-fold in P-gp and Mrp2 knockout rats. The sulfapyridine metabolite/ parent ratio was decreased 10-fold in rats lacking Bcrp after oral, but not intravenous, sulfasalazine. After intravenous administration, sulfasalazine exposure was 28% increased in Bcrp knockout rats despite 2.4-fold increased volume of distribution, consistent with the 25% decrease in clearance and 56% decrease in the sulfapyridine/parent ratio, neither of which achieved statistical significance. In Mrp2 knockout rats, the volume of distribution was increased 7.7-fold, resulting in decreased intravenous exposure and longer half-life. To establish potential perturbations in systemic pharmacokinetics of sulfasalazine and sulfapyridine in an established model lacking Mrp2, studies were also conducted in Mrp2-deficient Wistar (TR Ϫ ) rats ( Fig. 5 ; Table 4 ). Although a number of relatively modest, but statistically significant, differences were observed, the most notable change was observed in the volume of distribution, which was increased 3.4-fold in TR Ϫ rats, resulting in lower sulfasalazine exposures and longer half-life.
Carboxydichlorofluorescein pharmacokinetic and excretory parameters are summarized in Table 5 , and the corresponding concentrationtime profiles are presented in Fig. 6 . Carboxydichlorofluorescein biliary excretion was obliterated in Mrp2 knockout rats, resulting in 25% decreased systemic clearance and 32 to 35% increased exposure and half-life. Surprisingly in both Bcrp and Mdr1a knockout rats, carboxydichlorofluorescein exposure was decreased 28% due to significantly increased clearance, although dose recovery in excreta was not affected. Carboxydichlorofluorescein renal clearance was on average 0.64 to 1.5 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 , which is above the unbound glomerular filtration rate of 0.39 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 (glomerular 
TABLE 2

Paclitaxel pharmacokinetic and excretory parameters
Data are means Ϯ S.D. n ϭ 5 to 9 (n ϭ 6 to 12; bile duct-cannulated rats). filtration rate ϭ 5.24 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 ; plasma fraction unbound ϭ 7.4%), consistent with a contribution from an active secretory process in addition to passive filtration (Davies and Morris, 1993) . However, carboxydichlorofluorescein urinary excretion was unchanged in all knockouts, indicating that Mrp2, Bcrp, and P-gp are not involved in the active secretory process. Carboxydichlorofluorescein metabolic stability was confirmed in vitro using liver microsomes and hepatocytes, in which time-dependent loss of parent compound or formation of metabolite(s) related to the parent structure were not observed.
Discussion
Independent characterization of SAGE transporter knockout rats has not been reported to date, and validation is necessary before this model can be applied to address novel questions. Unpublished preliminary studies conducted by the vendor were consistent with the expected phenotypes, but these studies were very limited in scope. Oral digoxin concentrations were increased one order of magnitude in Mdr1a knockout rats; however, digoxin is not a specific P-gp probe and is also transported by Oatp's and Ost␣/␤, as well as undergoing appreciable metabolism in rodents (Lage and Spratt, 1965; KullakUblick et al., 2001; van Montfoort et al., 2002; Seward et al., 2003; Mdr1a Knockout Rat Data Sheet, 2011 , http://www.sageresearchmodels.com). CNS distribution of dantrolene was enhanced 3.7-fold in Bcrp knockout rats (Enokizono et al., 2008; Bcrp Knockout Rat Data Sheet, 2011 , http://www.sageresearchmodels.com). Mrp2 knockout rats exhibited the expected hereditary conjugated hyperbilirubinemia; serum and urine total bilirubin levels were increased 86-and 50-fold, respectively (Jansen et al., 1985; Mrp2 Knockout Rat Data Sheet, 2011 , http:// www.sageresearchmodels.com). More recently, enhancement of CNS distribution of seven P-gp substrates was compared between Mdr1a knockout mice and SAGE rats, and generally good agreement was observed between these two species (Bundgaard et al., 2012) .
In the present study, relevant aspects of loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics were systematically studied across SAGE Mdr1a, Bcrp, and Mrp2 knockout rats to confirm the relevant phenotype and investigate unexpected compensatory changes. Loperamide and paclitaxel were used as P-gp probes (Sparreboom et al., 1997; Kalvass et al., 2004) . Although loperamide transport interactions are limited to P-gp, paclitaxel is also transported by OATP1B3 and OAT2; in addition MRP2, but not MRP3 or MRP4, transported paclitaxel in vitro (Kool et al., 1999; Zeng et al., 1999; Lee et al., 2000; Huisman et al., 2005; Kobayashi et al., 2005; Smith et al., 2005) . Sulfasalazine was used to investigate potential changes in Bcrp activity, whereas carboxydichlorofluorescein was used as a probe for Mrp2 function (Zamek-Gliszczynski et al., 2003; Zaher et al., 2006) . Sulfasalazine undergoes extensive intestinal Bcrp efflux but is also effluxed by P-gp and Mrp2 to a low extent and is transported by OATP2B1 (Zaher et al., 2006; Dahan and Amidon, 2009; Kusuhara et al., 2012) . In addition to Mrp2, carboxydichlorofluorescein is also transported by Oatp1a1, Oatp1b2, and Mrp3 (Zamek-Gliszczynski et al., 2003) . SAGE Mdr1a knockout rats demonstrated the expected changes in loperamide and paclitaxel pharmacokinetics associated with the absence of P-gp in key drug disposition organs. Loperamide exposures were increased due to a 42% reduction in clearance and 2.2-fold increase in oral bioavailability. Clear opioid CNS effects were observed only in rats lacking P-gp. Overall, these findings are consistent with alterations in loperamide pharmacokinetics in established P-gp knockout models, which demonstrated 3.1-fold increased intestinal permeability, 65-fold enhanced CNS partitioning, and 25 to 50% reduction in systemic clearance (Adachi et al., 2003; Kalvass et al., 2004; Chu et al., 2012) . Likewise, paclitaxel exposures were increased in Mdr1a knockout rats owing to 40% decreased clearance and a 4-fold increase in oral bioavailability, and brain partitioning was increased 4-fold. These findings are generally consistent with paclitaxel disposition in established P-gp-deficient animal models, in which oral bioavailability was increased 3.1-fold, clearance was decreased 50%, and CNS distribution was on average increased 2-fold (Sparreboom et al., 1997; Gallo et al., 2003) . SAGE Bcrp knockout rats demonstrated the expected marked increase in sulfasalazine oral bioavailability (1.4% versus 30%), which was in good agreement with the 4 to 37% increase reported in mice (Zaher et al., 2006) . The relatively modest 2-to 3-fold increase in dmd.aspetjournals.org sulfasalazine bioavailability observed in the Mdr1a and Mrp2 knockout rats is also consistent with previous studies (Zaher et al., 2006; Dahan and Amidon, 2009 ). The 10-fold decrease in the sulfapyridine metabolite/parent ratio after oral sulfasalazine administration to Bcrp knockout rats is consistent with decreased exposure to intestinal metabolism in the absence of Bcrp efflux (Zaher et al., 2006) . Unlike Bcrp knockout mice, in which sulfasalazine clearance was decreased by one order of magnitude, the knockout rats demonstrated only a 25% decrease in clearance, which did not achieve statistical significance (Zaher et al., 2006) . Although the discrepancy in the impact of Bcrp ablation on sulfasalazine clearance is large, this drug is cleared primarily by metabolism and secondly by urinary excretion via glomerular filtration (Azulfidine prescribing information; Pfizer, Inc., 2011). Therefore, Bcrp knockout rats appear to better maintain sulfasalazine clearance than their murine counterpart. Sulfasalazine and sulfapyridine pharmacokinetics in an established Mrp2-deficient model are not reported in the literature and were therefore investigated in the present study. Hepatic Bcrp expression and function are decreased by one order of magnitude in TR Ϫ rats, but it is not known whether intestinal Bcrp is subject to the same downregulation (Yue et al., 2011) . Of note, the TR Ϫ rat did not exhibit increased sulfasalazine bioavailability, indicating that unlike in the liver, intestinal Bcrp activity is not decreased in these animals. As in SAGE Mrp2 knockout rats, the largest effect on sulfasalazine phar- macokinetics in TR Ϫ rats was increased volume of distribution, leading to reduced drug concentrations. The increased volume is probably the result of impaired cellular excretion of sulfasalazine in the absence of Mrp2 and low hepatic Bcrp function (Yue et al., 2011) .
Carboxydichlorofluorescein biliary excretion was obliterated in Mrp2 knockout rats, leading to increased systemic exposure and half-life due to reduced clearance. Carboxydichlorofluorescein is metabolically stable and Mrp2-mediated biliary excretion is a substantial contributor to overall systemic clearance (Zamek-Gliszczynski et al., 2003; Nezasa et al., 2006) . Renal clearance was not reduced in Mrp2 and other knockout rats, indicating that these three transporters are not involved in carboxydichlorofluorescein renal clearance.
The present characterization studies revealed a few phenotypic changes not directly attributed to the knocked-out transporters; however, these compensatory alterations are not unprecedented. The 61% decrease in paclitaxel liver partitioning in Mrp2 knockout rats may have resulted from compensatory up-regulation of metabolism. Naturally occurring Mrp2-deficient rats exhibit an increase in several hepatic clearance mechanisms, including certain glucuronidation, sulfation, and glutathione conjugation activities (Zamek-Gliszczynski et al., 2006a,b) . Although the increase in paclitaxel clearance in Mrp2 knockout rats did not attain statistical significance, a consistent trend of increased clearance of all non-Mrp2 probe substrates was observed in rats lacking Mrp2 (loperamide 30%, paclitaxel 36%, sulfasalazine 212%, and sulfasalazine 60% in TR Ϫ rats). In the absence of Mrp2, the liver is unable to excrete conjugated bile acids across the canalicular membrane, resulting in compensatory hepatic adjustments for the conjugated hyperbilirubinemia (Dubin and Johnson, 1954; Jansen et al., 1985; Hirohashi et al., 1998) .
The observation of increased carboxydichlorofluorescein clearance in Bcrp and Mdr1a knockout rats is also not unprecedented. Carboxydichlorofluorescein is metabolically stable, and its hepatic clearance occurs solely by biliary excretion via Mrp2 (Zamek-Gliszczynski et al., 2003; Nezasa et al., 2006) . In Bcrp knockout mice, a significant increase in carboxydichlorofluorescein biliary clearance was reported previously (Nezasa et al., 2006) . Several explanations for this observation were postulated, including up-regulation of Mrp2 and/or downregulation of hepatic basolateral efflux via Mrp3; however, hepatic Mrp2 and Mrp3 expression in Bcrp knockout mice was not altered, and so indirect transporter trafficking and/or stimulation/suppression by an endogenous Bcrp substrate were proposed instead (Nezasa et al., 2006) . Overall, these unexpected findings in Bcrp and P-gp knockout rats do not diminish their general utility because the primary importance of P-gp and Bcrp is in limiting intestinal absorption of low-permeability substrates, as well as CNS penetration of P-gp substrate drugs (Giacomini et al., 2010) . The few unexpected pharmacokinetic observations in SAGE knockout rats are in conceptual agreement with previously reported compensatory alterations in other P-gp, Bcrp, and Mrp2 knockout or mutant models (Nezasa et al., 2006; Zamek-Gliszczynski et al., 2006a,b; Chu et al., 2012) . However, the lack of expression data for absorption, distribution, metabolism, and excretion-relevant genes in SAGE knockout rats is a limitation of the present study. Compensatory changes reported in other models cannot be assumed to be exactly the same in SAGE knockout rats. For example, increased metabolic activity and hepatic Mrp3 up-regulation has been reported in Mrp2-deficient rats but was not observed in Mrp2 knockout mice (Hirohashi et al., 1998; Chu et al., 2006; Zamek-Gliszczynski et al., 2006a) . Future evaluation of mRNA and, where possible, protein expression in SAGE knockout rats is needed and may provide insight into some of the unexpected changes observed in the present study.
Overall, SAGE Mdr1a, Bcrp, and Mrp2 knockout rats demonstrated the expected phenotypes with respect to alterations in pharmacokinetics of relevant probe substrates. A few compensatory changes were observed, but these are not unique to the SAGE knockout rats and have been reported in established models previously. The data support the use of these knockout rats as an alternative to murine models whenever a larger species is practically advantageous or more relevant. 
